Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Memotine SCHEMBL147540 | 0.99 | PKM (0.48) | ALDH1A1KDM4EPKMLMNAMAOA | |
| Famotine SCHEMBL600861 | 0.86 | ALDH1A1 (0.47) | ALDH1A1KDM4EPKMLMNAMAOA | |
| Famotine SCHEMBL32677713 | 0.84 | ALDH1A1 (0.46) | ALDH1A1KDM4EPKMLMNAMAOA | |
| Famotine SCHEMBL147773 | 0.84 | ALDH1A1 (0.46) | ALDH1A1KDM4EPKMLMNAMAOA | |
| SCHEMBL7338667 | 0.82 | KDM4E (0.54) | ALDH1A1KDM4EPKMLMNAMAOA | |
| SCHEMBL7509399 | 0.78 | KDM4E (0.60) | ALDH1A1KDM4ELMNAMAOAMAPT | |
| SCHEMBL29361631 | 0.78 | KDM4E (0.60) | ALDH1A1KDM4ELMNAMAOAMAPT | |
| SCHEMBL12567716 | 0.75 | ALDH1A1 (0.65) | ALDH1A1PKMLMNAMAOANOS3 | |
| SCHEMBL29498350 | 0.75 | ALDH1A1 (0.65) | ALDH1A1PKMLMNAMAOANOS3 | |
| SCHEMBL29498357 | 0.75 | ALDH1A1 (0.65) | ALDH1A1PKMLMNAMAOANOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4262812-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | Southern Research Institute (US) | 2023-10-25 | — | — | EP | claimed |
| WO-2023122212-A2 | SUBSTITUTED PHENYL ETHYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | claimed |
| EP-4125845-A1 | NOVEL 2-PYRIMIDONE ANALOGS AS POTENT ANTIVIRAL AGENTS AGAINST ALPHAVIRUSES | Southern Research Institute (US) | 2023-02-08 | — | — | EP | claimed |
| EP-4021413-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2022133323-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2022-06-23 | — | — | WO | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-4092139-B1 | METHOD FOR DISCRIMINATING BETWEEN LIVE AND DEAD MICROBES IN A SAMPLE | PATHOQUEST (FR) | 2026-02-18 | — | — | EP | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-20250144066-A1 | Prevention and Treatment of Parasitic Infections | BARANOWITZ STEVEN (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025064458-A1 | PREVENTION AND TREATMENT OF VIRAL INFECTIONS | BARANOWITZ STEVEN (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-3810811-B1 | METHOD FOR DISCRIMINATING BETWEEN LIVE AND DEAD MICROBES IN A SAMPLE | PATHOQUEST (FR) | 2022-06-15 | — | — | EP | disclosed |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-09 | — | — | US | disclosed |
| WO-2022117764-A1 | FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF | INSTITUT CURIE (FR) | 2022-06-09 | — | — | WO | disclosed |
| CN-114502174-A | 2,4,7 substituted-7-deaza-2 '-deoxy-2' -fluoroarabinosucleosides and nucleotide prodrugs and use thereof | 南方研究院 | 2022-05-13 | — | — | CN | disclosed |
| EP-3982976-A2 | 2,4,7-SUBSTITUTED-7-DEAZA-2'-DEOXY-2'-FLUOROARABINOSYL NUCLEOSIDE AND NUCLEOTIDE PRO-DRUGS AND USES THEREOF | Southern Research Institute (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3980057-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | Institut Curie (FR) | 2022-04-13 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | ALDH1A1 4838/4885KDM4E 2432/4885PKM 4689/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | ALDH1A1 4710/4885KDM4E 2972/4885PKM 4207/4885 |
| US-20250144066-A1 | Prevention and Treatment of Parasitic Infections | EPX, CTSA, SERPINB1 | ALDH1A1 509/4885KDM4E 4297/4885PKM 2375/4885 |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | ALDH1A1 492/4885KDM4E 470/4885PKM 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.